Abbott Laboratories (NYSE:ABT) recently introduced the FreeStyle Libre 3 Plus in Canada, marking an advancement in diabetes management technology with its small, sensor-based glucose monitoring ...

"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly ...

Abbott posted Q2 revenue of $11.14 billion and EPS of $1.26, raised 2025 earnings guidance, and saw strong growth in diabetes ...

Abbott beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its medical devices, including continuous glucose monitors.

Q2 2025 Earnings Call Transcript July 17, 2025 Abbott Laboratories reports earnings inline with expectations. Reported EPS is ...

Discover Abbott Laboratories' Q2 2025 highlights: resilience drives high single-digit growth, double-digit EPS, and pipeline innovations.

Investing.com -- Abbott Laboratories reported second-quarter earnings that slightly exceeded analyst expectations, but shares ...

Abbott’s sales of continuous glucose monitors were $1.9 billion in the second quarter, marking a growth of 21.4% on a ...

Medical Devices achieved strong double-digit growth, while the Diagnostics segment in China saw ongoing pressure. These 10 stocks could mint the next wave of millionaires › Abbott Laboratories ...

New research from investigators at Mass General Brigham suggests that a commonly used type 2 diabetes medication is linked to a higher rate of heart-related conditions compared to medications that hit ...